Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus

doi:10.1007/s13659-012-0021-4

应用天然产物 ›› 2012, Vol. 2 ›› Issue (3): 104-110.DOI: 10.1007/s13659-012-0021-4

Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus

Jonathan P. HUANG^a, Nazia MOJIB^a,e, Rakesh R. GOLI^a, Samantha WATKINS^a, Ken B. WAITES^b, Rasik RAVINDRA^c, Dale T. ANDERSEN^d, Asim K. BEJ^a

a Department of Biology, University of Alabama at Birmingham, Birmingham, AL 35294-1170, USA;
b Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294-1170, USA;
c National Centre for Antarctic & Ocean Research, Head Land Sada, Vasco-da-Gama Goa 403804, India;
d Carl Sagan Center for the Study of Life in the Universe, SETI Institute, Mountain View, CA 94043, USA;
e Red Sea Research Center, King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia

收稿日期:2012-03-11 修回日期:2012-03-21 出版日期:2012-06-24 发布日期:2018-02-11
通讯作者: Asim K.BEJ,E-mail:abej@uab.edu
基金资助:
We thank Col.(IL) J. N. Pritzker ARNG(Retired), Tawani Foundation(Chicago) for supporting the Tawani 2008 International Antarctic Scientific Expedition;Marty Kress, VCSI, Inc. /NASA;Richard Hoover, NASA;and 2008-2009 Antarctic Maitri(India) and Novolazarevskaya(Russia) Station staffs.

Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus

Jonathan P. HUANG^a, Nazia MOJIB^a,e, Rakesh R. GOLI^a, Samantha WATKINS^a, Ken B. WAITES^b, Rasik RAVINDRA^c, Dale T. ANDERSEN^d, Asim K. BEJ^a

a Department of Biology, University of Alabama at Birmingham, Birmingham, AL 35294-1170, USA;
b Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294-1170, USA;
c National Centre for Antarctic & Ocean Research, Head Land Sada, Vasco-da-Gama Goa 403804, India;
d Carl Sagan Center for the Study of Life in the Universe, SETI Institute, Mountain View, CA 94043, USA;
e Red Sea Research Center, King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia

Received:2012-03-11 Revised:2012-03-21 Online:2012-06-24 Published:2018-02-11
Supported by:
We thank Col.(IL) J. N. Pritzker ARNG(Retired), Tawani Foundation(Chicago) for supporting the Tawani 2008 International Antarctic Scientific Expedition;Marty Kress, VCSI, Inc. /NASA;Richard Hoover, NASA;and 2008-2009 Antarctic Maitri(India) and Novolazarevskaya(Russia) Station staffs.

摘要/Abstract

摘要： Multiple drug resistant(MDR) and methicillin-resistant Staphylococcus aureus(MRSA) have become increasingly prevalent as a community acquired infection. As a result limited treatment options are available with conventional synthetic antibiotics. Bioprospecting natural products with potent antimicrobial activity show promise for developing new drugs against this pathogen. In this study, we have investigated the antimicrobial activity of a purple violet pigment(PVP) from an Antarctic bacterium, Janthinobacterium sp. Ant5-2 on 15 clinical MDR and MRSA strains. The colorimetric resazurin assay was employed to determine the minimum inhibitory concentration(MIC₉₀) of PVP against MDR and MRSA. The MIC₉₀ ranged between 1.57 μg/mL and 3.13 μg/mL, which are significantly lower than many antimicrobials tested from natural sources against this pathogen. The spectrophotometrically determined growth analysis and total microscopic counts using Live/dead® BacLight^TM fluorescent stain exhibited a steady decrease in viability of both MDR and MRSA cultures following treatment with PVP at the MIC levels. In silico predictive molecular docking study revealed that PVP could be a DNA-targeting minor groove binding antimicrobial compound. The continued development of novel antimicrobials derived from natural sources with the combination of a suite of conventional antibiotics could stem the rising pandemic of MDR and MRSA along with other deadly microbial pathogens.

关键词: natural product, bacterial pigment, resazurin assay, minimum inhibitory concentration(MIC)

Abstract: Multiple drug resistant(MDR) and methicillin-resistant Staphylococcus aureus(MRSA) have become increasingly prevalent as a community acquired infection. As a result limited treatment options are available with conventional synthetic antibiotics. Bioprospecting natural products with potent antimicrobial activity show promise for developing new drugs against this pathogen. In this study, we have investigated the antimicrobial activity of a purple violet pigment(PVP) from an Antarctic bacterium, Janthinobacterium sp. Ant5-2 on 15 clinical MDR and MRSA strains. The colorimetric resazurin assay was employed to determine the minimum inhibitory concentration(MIC₉₀) of PVP against MDR and MRSA. The MIC₉₀ ranged between 1.57 μg/mL and 3.13 μg/mL, which are significantly lower than many antimicrobials tested from natural sources against this pathogen. The spectrophotometrically determined growth analysis and total microscopic counts using Live/dead® BacLight^TM fluorescent stain exhibited a steady decrease in viability of both MDR and MRSA cultures following treatment with PVP at the MIC levels. In silico predictive molecular docking study revealed that PVP could be a DNA-targeting minor groove binding antimicrobial compound. The continued development of novel antimicrobials derived from natural sources with the combination of a suite of conventional antibiotics could stem the rising pandemic of MDR and MRSA along with other deadly microbial pathogens.

Key words: natural product, bacterial pigment, resazurin assay, minimum inhibitory concentration(MIC)

Jonathan P. HUANG, Nazia MOJIB, Rakesh R. GOLI, Samantha WATKINS, Ken B. WAITES, Rasik RAVINDRA, Dale T. ANDERSEN, Asim K. BEJ. Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus[J]. 应用天然产物, 2012, 2(3): 104-110.

参考文献

[1] Gould, I. M. J. Hosp. Infect. 2005, 61, 277-282.
[2] Archer, G. L. Clin. Infect. Dis. 1998, 26, 1179-1181.
[3] Hidayat, L. K.; Hsu, D. I.; Quist, R.; Shriner, K. A.; WongBeringer, A. Arch. Intern. Med. 2006, 166, 2138-2144.
[4] Chambers, H. F. Emerg. Infect. Dis. 2001, 7, 178-182.
[5] David, M. Z.; Daum, R. S. Clin. Microbiol. Rev. 2010, 23, 616-687.
[6] Klein, E.; Smith, D. L.; Laxminarayan, R. Emerg. Infect. Dis. 2007, 13, 1840-1846.
[7] Critchley, I. A.; Blosser-Middleton, R. S.; Jones, M. E.; Thornsberry, C.; Sahm, D. F.; Karlowsky, J. A. Antimicrob. Agents Chemother. 2003, 47, 1689-1693.
[8] Ardic, N.; Ozyurt, M.; Sareyyupoglu, B.; Haznedaroglu, T. Int. J. Antimicrob. Agents 2005, 26, 213-218.
[9] Frazee, B. W.; Lynn, J.; Charlebois, E. D.; Lambert, L.; Lowery, D.; Perdreau-Remington, F. Ann. Emerg. Med. 2005, 45, 311-320.
[10] Kuroda, M. et al. Lancet 2001, 357, 1225-1240.
[11] Enright, M. C.; Robinson, D. A.; Randle, G.; Feil, E. J.; Grundmann, H.; Spratt, B. G. Proc. Natl. Acad. Sci. USA 2002, 99, 7687-7692.
[12] Clardy, J.; Fischbach, M. A.; Walsh, C. T. Nat. Biotechnol. 2006, 24, 1541-1550.
[13] Brady, A.; Loughlin, R.; Gilpin, D.; Kearney, P.; Tunney, M. J. Med. Microbiol. 2006, 55, 1375-1380.
[14] Obiang-Obounou, B. W.; Kang, O. H.; Choi, J. G.; Keum, J. H.; Kim, S. B.; Mun, S. H.; Shin, D. W.; Kim, K. W.; Park, C. B.; Kim, Y. G.; Han, S. H.; Kwon, D. Y. J. Toxicol. Sci. 2011, 36, 277-283.
[15] Chung, P. Y.; Navaratnam, P.; Chung, L. Y. Ann. Clin. Microbiol. Antimicrob. 2011, 10, 25-31.
[16] Yu, Y. Y.; Wang, H.; Zhang, S. W.; Wang, B. E. Chin. Med. J. 2010, 123, 1017-1020.
[17] Pesewu, G. A.; Cutler, R. R.; Humber, D. P. J. Ethnopharmacol. 2008, 116, 102-111.
[18] Molinski, T. F.; Faulkner, D. J. Tetrahedron Lett. 2001, 29, 2137-2138.
[19] Lo Giudice, A.; Bruni, V.; Michaud, L. J. Basic Microbiol. 2007, 47, 496-505.
[20] Mojib, N.; Philpott, R.; Huang, J. P.; Niederweis, M.; Bej, A. K. Antonie Van Leeuwenhoek 2010, 98, 531-540.
[21] Desnottes, J. F. Trend Biotechnol. 1996, 14, 134-140.
[22] Mojib, N.; Nasti, T. H.; Andersen, D. T.; Attigada, V. R.; Hoover, R. B.; Yusuf, N.; Bej, A. K. Int. J. Dermatol. 2011, 50, 1223-1233.
[23] Anoopkumar-Dukie, S.; Carey, J. B.; Conere, T.; O'sullivan, E.; van Pelt, F. N.; Allshire, A. Br. J. Radiol. 2005, 78, 945-947.
[24] Duarte, M.; Giordani, R. B.; De Carli, G. A.; Zuanazzi, J. A.; Macedo, A. J.; Tasca, T. Exp. Parasitol. 2009, 123, 195-198.
[25] Martin, A.; Camacho, M.; Portaels, F.; Palomino, J. C. Antimicrob. Agents Chemother. 2003, 47, 3616-3619.
[26] Martin, A.; Morcillo, N.; Lemus, D.; Montoro, E.; Telles, M. A.; Simboli, N.; Pontino, M.; Porras, T.; León, C.; Velasco, M.; Chacon, L.; Barrera, L.; Ritacco, V.; Portaels, F.; Palomino, J. C. Int. J. Tuberc. Lung Dis. 2005, 9, 901-906.
[27] Rivoire, N.; Ravololonandriana, P.; Rasolonavalona, T.; Martin, A.; Portaels, F.; Ramarokoto, H.; Rasolofo Razanamparany, V. Int. J. Tuberc. Lung Dis. 2007, 11, 683-688.
[28] Sanchez, J. G. B.; Kouzetsov, V. V. Braz. J. Microbiol. 2010, 41, 270-277.
[29] Hsieh, P. C.; Siegel, S. A.; Rogers, B.; Davis, D.; Lewis, K. Proc. Natl. Acad. Sci. USA 1998, 95, 6602-6606.
[30] Piddock, L. J. V. Clin. Microbiol. 2006, 19, 382-402.
[31] Durai, R.; Ng, P. C.; Hoque, H. AORN. J. 2010, 91, 599-606.
[32] Dharmaratne, H. R. W.; Wijesinghe, W. M. N. M.; Thevanasem, V. J. Ethnopharmacol. 1999, 66, 339-342.
[33] Cutler, R. R.; Wilson, P. Br. J. Biomed. Sci. 2005, 61, 71-74.
[34] Martins, D.; Costa, F. T. M.; Brocchi, M.; Duran, N. J. Nanopart. Res. 2011, 13, 355-363.
[35] Mustaffa, F.; Indurkar, J.; Ismail, S.; Shah, M.; Mansor, S. M. Molecules 2011, 16, 3037-3047.
[36] Vera, N.; Solorzano, E.; Ordonez, R.; Maldonado, L.; Bedascarrasbure, E.; Isla, M. I. Nat. Prod. Commun. 2011, 6, 823-827.
[37] Choi, J. G.; Kang, O. H.; Lee, Y. S.; Oh, Y. C.; Chae, H. S.; Obiang-Obounou, B.; Park, S. C.; Shin, D. W.; Hwang, B. Y.; Kwon, D. Y. Eur. Rev. Med. Pharmacol. Sci. 2010, 14, 1005-1009.
[38] Sianglum, W.; Srimanote, P.; Wonglumsom, W.; Kittiniyom, K.;Voravuthikunchai, S. P. PLoS One 2011, 6, e16628.
[39] Chew, Y. L.; Chan, E. W.; Tan, P. L.; Lim, Y. Y.; Stanslas, J.; Goh, J. K. BMC Complement Altern. Med. 2011, 11, 12.
[40] Jeong, S. I.; Kim, S. Y.; Kim, S. J.; Hwang, B. S.; Kwon, T. H.; Yu, K. Y.; Hang, S. H.; Suzuki, K.; Kim, K. J. Molecules 2010, 15, 7395-7402.
[41] Mulyaningsih, S.; Youns, M.; El-Readi, M. Z.; Ashour, M. L.; Nibret, E.; Sporer, F.; Herrmann, F.; Reichling, J.; Wink, M. J. Pharm. Pharmacol. 2010, 62, 1037-1044.
[42] Hannan, A.; Saleem, S.; Chaudhary, S.; Barkaat, M.; Arshad, M. U. J. Ayub. Med. Coll. Abbottabad. 2008, 20, 72-74.
[43] Wang, G.; Hindler, J. F.; Ward, K. W.; Bruckner, D. A. J. Clin. Microbiol. 2006, 44, 3883-3886.
[44] Nightingale, C. H.; Ambrose, P. G.; Drusano, G. L.; Murakawa, T. (eds.) Antimicrobial pharmacodynamics in theory and clinical practice (Infectious Disease and Therapy). Informa Heathcare:New York, 2nd ed. 2007; p 239-266.
[45] Cenizal, M. J.; Skiest, D.; Luber, S.; Bedimo, R.; Davis, P.; Fox, P.; Delaney, K.; Hardy, R. D. Antimicrob. Agents Chemother. 2007, 51, 2628-2630.
[46] Reeves, D. S.; Holt, H. A.; Phillips, I.; King, A.; Miles, R. S.; Paton, R.; Wise, R.; Andrews, J. M. J. Antimicrob. Chemother. 1991, 27, 469-474.
[47] Wilson, A. P.; Cepeda, J. A.; Hayman, S.; Whitehouse, T.; Singer, M.; Bellingan, G. J. Antimicrob. Chemother. 2006, 58, 470-473.
[48] Panchal, R. G.; Ulrich, R. L.; Lane, D.; Butler, M. M.; Houseweart, C.; Opperman, T.; Williams, J. D.; Peet, N. P.; Moir, D. T.; Nguyen, T.; Gussio, R.; Bowlin, T.; Bavari, S. Antimicrob. Agents Chemother. 2009, 53, 4283-4291.
[49] Butler, M. M.; Williams, J. D.; Peet, N. P.; Moir, D. T.; Panchal, R. G.; Bavari, S.; Shinabarger, D. L.; Bowlin, T. L. Antimicrob. Agents Chemother. 2010, 54, 3974-3977.
[50] Palchaudhuri, R.; Hergenrother, P. J. Curr. Opin. Biotechnol. 2007, 18, 497-503.
[51] Chaires, J. B. Biopolymers 1997, 44, 201-215.
[52] Ricci, C. G.; Netz, P. A. J. Chem. Inf. Model. 2009, 49, 1925-2935.
[53] Martineau, F.; Picard, F. J.; Roy, P. H.; Ouellette, M.; Bergeron, M. G. J. Clin. Microbiol. 1998, 36, 618-623.
[54] Reischl, U.; Linde, H. J.; Metz, M.; Leppmeier, B.; Lehn, N. J. Clin. Microbiol. 2000, 38, 2429-2433.
[55] Shrestha, N. K.; Tuohy, M. J.; Hall, G. S.; Isada, C. M.; Procop, G. W. J. Clin. Microbiol. 2002, 40, 2659-2661.
[56] Ausubel, F. M.; Brent, R.; Kingston, R. E.; Moore, D. D.; Smith, J. G.; Sideman, J. G.; Struhl, K. (eds.) Current protocols in molecular biology. John Wiley & Sons, Inc:New York, 1987.
[57] Rettori, D.; Duran, N. World J. Microbiol. Biotechnol. 1998, 14, 685-688.
[58] Sarker, S. D.; Nahar, L.; Kumarasamy, Y. Methods 2007, 42, 321-324.
[59] Boulos, L.; Prévost, M.; Barbeau, B.; Coallier, J.; Desjardins, R. J. Microbiol. Methods 1999, 37, 77-86.
[60] Auty, M. A.; Gardiner, G. E.; McBrearty, S. J.; O'Sullivan, E. O.; Mulvihill, D. M.; Collins, J. K.; Fitzgerald, G. F.; Stanton, C.; Ross, R. P. Appl. Environ. Microbiol. 2001, 67, 420-425.
[61] Ritchie, D. W.; Venkatraman, V. Bioinformatics 2010, 26, 2398-2405.
[62] Leite, T. B.; Gomes, D.; Miteva, M. A.; Chomilier, J.; Villoutreix, B. O.; Tuffery, P. Nucleic Acids Res. 2007, 35, W568-572.

Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus

Antimicrobial activity of PVP from an Antarctic bacterium, Janthinobacterium sp. Ant5-2, on multi-drug and methicillin resistant Staphylococcus aureus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	Haoqi Dong, Xinni Yang, Peiying Wang, Weiya Huang, Liang Zhang, Song Song, Jiangxin Liu. Identification and verification of methylenetetrahydrofolate dehydrogenase 1-like protein as the binding target of natural product pseudolaric acid A[J]. 应用天然产物, 2025, 15(3): 21-21.
[2]	Hesham R. El-Seedi, Mohamed S. Refaey, Nizar Elias, Mohamed F. El-Mallah, Faisal M. K. Albaqami, Ismail Dergaa, Ming Du, Mohamed F. Salem, Haroon Elrasheid Tahir, Maria Dagliaa, Nermeen Yosri, Hongcheng Zhang, Awg H. El-Seedi, Zhiming Guo, Shaden A. M. Khalifa. Marine natural products as a source of novel anticancer drugs: an updated review (2019-2023)[J]. 应用天然产物, 2025, 15(2): 13-13.
[3]	Xiaoxia Gu, Xiaotian Zhang, Xueke Zhang, Xinyu Wang, Weiguang Sun, Yonghui Zhang, Zhengxi Hu. Unveiling the mechanism of action of a novel natural dual inhibitor of SARS-CoV-2 Mpro and PLpro with molecular dynamics simulations[J]. 应用天然产物, 2025, 15(1): 3-3.
[4]	María I. Osella, Mario O. Salazar, Carlos M. Solís, Ricardo L. E. Furlan. New semisynthetic α-glucosidase inhibitor from a doubly-chemically engineered extract[J]. 应用天然产物, 2025, 15(1): 4-4.
[5]	Ahmed H. Elbanna, Xinhui Kou, Dilip V. Prajapati, Surasree Rakshit, Rebecca A. Butcher. Discovery of a parallel family of euglenatide analogs in Euglena gracilis[J]. 应用天然产物, 2025, 15(1): 10-10.
[6]	Song-Yu Hou, Bing-Chao Yan, Han-Dong Sun, Pema-Tenzin Puno. Recent advances in the application of [2+2] cycloaddition in the chemical synthesis of cyclobutane-containing natural products[J]. 应用天然产物, 2024, 14(5): 37-37.
[7]	Felaine Anne Sumang, Alan Ward, Jeff Errington, Yousef Dashti. Hibiscus acid and hydroxycitric acid dimethyl esters from Hibiscus flowers induce production of dithiolopyrrolone antibiotics by Streptomyces Strain MBN2-2[J]. 应用天然产物, 2024, 14(5): 40-40.
[8]	Chunsong Hu. Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease[J]. 应用天然产物, 2024, 14(2): 2-2.
[9]	Shohreh Ariaeenejad, Javad Gharechahi, Mehdi Foroozandeh Shahraki, Fereshteh Fallah Atanaki, Jian-Lin Han, Xue-Zhi Ding, Falk Hildebrand, Mohammad Bahram, Kaveh Kavousi, Ghasem Hosseini Salekdeh. Precision enzyme discovery through targeted mining of metagenomic data[J]. 应用天然产物, 2024, 14(1): 7-7.
[10]	Daniel W. Armstrong, Alain Berthod. Occurrence of D-amino acids in natural products[J]. 应用天然产物, 2023, 13(6): 47-47.
[11]	Xinxin Li, Runlu Shi, Lingchen Yan, Weiwei Chu, Ruishuang Sun, Binkai Zheng, Shuai Wang, Hui Tan, Xusheng Wang, Ying Gao. Natural product rhynchophylline prevents stress-induced hair graying by preserving melanocyte stem cells via the β2 adrenergic pathway suppression[J]. 应用天然产物, 2023, 13(6): 54-54.
[12]	Dalila Carbone, Carmela Gallo, Genoveffa Nuzzo, Giusi Barra, Mario Dell'Isola, Mario Affuso, Olimpia Follero, Federica Albiani, Clementina Sansone, Emiliano Manzo, Giuliana d'Ippolito, Angelo Fontana. Marine natural product lepadin A as a novel inducer of immunogenic cell death via CD91-dependent pathway[J]. 应用天然产物, 2023, 13(5): 34-34.
[13]	Phanankosi Moyo, Luke Invernizzi, Sephora M. Mianda, Wiehan Rudolph, Warren A. Andayi, Mingxun Wang, Neil R. Crouch, Vinesh J. Maharaj. Leveraging off higher plant phylogenetic insights for antiplasmodial drug discovery[J]. 应用天然产物, 2023, 13(5): 35-35.
[14]	Phanankosi Moyo, Luke Invernizzi, Sephora M. Mianda, Wiehan Rudolph, Andrew W. Andayi, Mingxun Wang, Neil R. Crouch, Vinesh J. Maharaj. Prioritised identification of structural classes of natural products from higher plants in the expedition of antimalarial drug discovery[J]. 应用天然产物, 2023, 13(5): 37-37.
[15]	Ji-Kai Liu. Natural products in cosmetics[J]. 应用天然产物, 2022, 12(6): 40-40.